Drug intelligence / Profile preview

GCQID

Development stage: Preclinical
Administration: Oral

Overview

GCQID is a multi-ingredient dietary supplement that was investigated in a pilot study for its potential to improve locomotor functions and relieve knee pain. The supplement's composition includes 1,200 mg of glucosamine hydrochloride, 60 mg of chondroitin sulfate (from shark cartilage extract), 45 mg of type II collagen peptides (from shark cartilage extract), 90 mg of quercetin glycosides, 10 mg of imidazole peptides (anserine and carnosine, from fish meat extract), and 5 μg of vitamin D.

Beyond the preview

Go deeper on GCQID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCQID.

Explore the full profile